Hawaiian Airlines v. Dept. of Taxation - Tax Appeal Certiorari Rejected

The Hawaii Supreme Court rejected Hawaiian Airlines' petition for writ of certiorari in a tax appeal case against the Hawaii Department of Taxation. The Intermediate Court of Appeals decision (CAAP-24-0000496) will stand as the final judgment. The certiorari application, filed February 3, 2026, was rejected by order dated March 31, 2026.

Tiki's Grill v. DTRIC Insurance - Certiorari Accepted

The Hawaii Supreme Court accepted DTRIC Insurance Company Limited's Application for Writ of Certiorari in Case No. SCWC-22-0000084. The case involves an insurance coverage dispute originating from Circuit Court Case No. 1CCV-20-0001213 and previously decided by the Intermediate Court of Appeals. The matter will be scheduled for oral argument before the state's highest court.

West Physicians Associates v. Quiane - Motion for Reconsideration Denied

The Hawaii Intermediate Court of Appeals denied Defendant-Appellant Agrifina Quiane's Motion for Reconsideration of the court's March 25, 2026 order granting a motion to dismiss the appeal. All pending motions in the case are dismissed.

Gonsalves Revocable Trust Case - Probate Appeal

The Hawaii Intermediate Court of Appeals vacated and remanded the Probate Court of the First Circuit's January 31, 2024 judgment in the Henry L. Gonsalves Revocable Trust case. The appellate court found structural error where the probate court denied Celeste M. Gonsalves's petition to amend the Trust and awarded attorneys' fees without first entering a written order retaining the case under Hawaii Probate Rules Rule 20(a). The case is remanded for further proceedings consistent with HPR Rule 20(a) requirements.

Wu v. United States Citizenship and Immigration Services - Immigration Action

Nanjie Wu filed a civil complaint against U.S. Citizenship and Immigration Services in the Northern District of California (Case No. 3:26-cv-02809). The complaint, filed on March 31, 2026, was submitted with a filing fee of $405 (receipt ACANDC-21820335). The case is categorized under Other Immigration Actions nature of suit.

In Re Stem, Inc. Derivative Litigation

The U.S. District Court for the District of Delaware issued an opinion in derivative shareholder litigation involving Stem, Inc., Case No. 23-1011 before Judge Maryellen Noreika. The court filing occurred on March 31, 2026. This is a derivative action, typically brought by shareholders on behalf of the corporation against officers or directors for alleged breaches of fiduciary duty.

Big Lots Inc. Bankruptcy Opinion

The United States District Court for the District of Delaware issued an opinion in Big Lots, Inc. bankruptcy case 25-130 on March 30, 2026. Judge Gregory B. Williams authored the opinion addressing matters before the court in this Chapter 11 bankruptcy proceeding involving the distressed retailer.

Big Lots Inc. Bankruptcy Case

The District Court of Delaware issued a bankruptcy court opinion in In Re: Big Lots, Inc., et al., Case No. 25-078. Judge Gregory B. Williams presided over this Chapter 11 bankruptcy proceeding involving the discount retailer. This is a routine bankruptcy filing with no immediate regulatory implications for other entities.

Big Lots, Inc. Bankruptcy Case

The District Court of Delaware issued an opinion in the Big Lots, Inc. bankruptcy case (Case 25-072) before Judge Gregory B. Williams on March 30, 2026. The court filing represents a routine bankruptcy proceeding involving the retail company Big Lots, Inc. and its affiliates.

FDA Identifies Serious Liver Injury Cases and Deaths with Tavneos

FDA issued a Drug Safety Communication alerting healthcare professionals and patients about serious postmarketing cases of drug-induced liver injury (DILI), including fatal outcomes, associated with Tavneos (avacopan). FDA identified 76 cases of DILI with reasonable evidence of causal association, including 8 deaths and 54 hospitalizations; some cases involved vanishing bile duct syndrome (VBDS). Healthcare professionals are now advised to conduct enhanced liver monitoring (every 2 weeks for the first month, then monthly for 5 months) and to discontinue treatment if liver enzymes exceed specified thresholds.